Novavax reports Q4 2022 revenue $357M, net loss $182M; raises going concern doubt

NOVAVAX INC

2022-FY EPS reported -$8.42 revenue$1,981,872,000

Q4 revenue $357M (+61% YoY), full year $1.9B (+73% YoY); net loss Q4 $182M, full year $658M.
Cash $1.3B as of Dec 31, 2022; raised $250M in convertible notes and equity in Dec 2022.
Appointed John C. Jacobs as President and CEO; raised going concern doubt about ability to continue through next year.
Updated US government agreement for up to 1.5M additional doses in 2023; initiated Phase 2 trial for COVID-19-Influenza combo vaccine.
Expanded Nuvaxovid label in adult booster and adolescent primary series.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NOVAVAX INC reported full year 2022 results: revenue $1.9 billion.

Period: full year 2022
Revenue: $1.9 billion
Result: reported results

Exact text from the filing

Total revenue for the full year 2022 was $1.9 billion

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NOVAVAX INC reported fourth quarter 2022 results: revenue $357 million.

Period: fourth quarter 2022
Revenue: $357 million
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter 2022 was $357 million

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-23-026709

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.